Purpose of this Study
Participants will be randomly assigned to receive either standard treatment after surgery or standard treatment plus an additional radiation treatment called I²-PORT. Standard treatment may include chemotherapy, immunotherapy, or no further treatment, depending on the participant’s medical care plan. Researchers will compare the two approaches to see if adding I²-PORT improves outcomes for people with non-small cell lung cancer.
Who Can Participate?
Eligibility
Participants may be able to join if they are adults with non-small cell lung cancer that has not spread to other parts of the body and have remaining cancer in nearby lymph nodes after treatment before surgery and complete tumor removal surgery. They cannot have certain genetic changes called EGFR mutations or ALK rearrangements, must be able to carry out most daily activities, and cannot be pregnant.
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
This study is comparing standard treatment alone with standard treatment plus I²-PORT radiation therapy after surgery for non-small cell lung cancer. Researchers want to learn if adding I²-PORT can help prevent the cancer from returning.
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
Yes
Study Details
Full Title
Protocol A082402, “Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-Port) for Resected Non-Small Cell Lung Cancer with Residual Mediastinal Adenopathy after Neoadjuvant Therapy (ypn2))
Principal Investigator
Trey
Mullikin
Protocol Number
PRO00121091
NCT ID
NCT07293247
Phase
II
Enrollment Status
Open to Enrollment